Provided by Tiger Trade Technology Pte. Ltd.

Merck

129.38
+0.72000.56%
Pre-market: 128.95-0.4300-0.33%04:56 EDT
Volume:9.58M
Turnover:1.24B
Market Cap:321.12B
PE:36.18
High:129.97
Open:127.65
Low:126.74
Close:128.66
52wk High:129.97
52wk Low:76.66
Shares:2.48B
Float Shares:2.48B
Volume Ratio:0.74
T/O Rate:0.39%
Dividend:3.28
Dividend Rate:2.54%
EPS(TTM):3.58
EPS(LYR):7.28
ROE:18.94%
ROA:12.58%
PB:7.00
PE(LYR):17.77

Loading ...

FDA Approves Keytruda® (pembrolizumab) and Keytruda Qlex™ (pembrolizumab and Berahyaluronidase Alfa-pmph), Each with Trodelvy® (sacituzumab Govitecan-hziy) as First-line Treatment of Pd-l1+ (CPS ≥10) Advanced Triple-negative Breast Cancer (tnbc)

THOMSON REUTERS
·
Jun 25

Alerts Incorrectly Tagged to Merck & Co Withdrawn

Reuters
·
Jun 25

Major Deals Involving US Drugmakers and Biotechs over the Past Decade

Reuters
·
Jun 25

Germany's Merck Boosts Life Sciences Business with $11 Billion Bet on Bio-techne

Reuters
·
Jun 25

Merck Reviews Regional Distribution Hub Plan In Abu Dhabi

MT Newswires Live
·
Jun 25

Department of Health Abu Dhabi: Partnership with Msd to Advance Operational Excellence and Expand Access Across Region

THOMSON REUTERS
·
Jun 25

Merck Initiated at Outperform by CICC

Dow Jones
·
Jun 25

Unicef, Gavi Call to Speed Bundibugyo Ebola Vaccine Access

Reuters
·
Jun 25

Merck says EC approves Keytruda plus Padcev combination

TIPRANKS
·
Jun 24

EU Approves Merck Keytruda Plus Padcev for Cisplatin-ineligible Resectable Muscle-invasive Bladder Cancer

Reuters
·
Jun 24

European Commission Approves Keytruda® (pembrolizumab) Plus Padcev® (enfortumab Vedotin-ejfv) as First Pd-1 Inhibitor Plus Antibody-drug Conjugate Regimen for Adults with Cisplatin-ineligible Resectable Muscle-invasive Bladder Cancer

THOMSON REUTERS
·
Jun 24

PharmaMar’s Partner Merck Seeks Priority Approval in Japan for Zepzelca as First-Line SCLC Maintenance

TIPRANKS
·
Jun 24

CICC Initiates Merck & Co. at Outperform With $138 Price Target

MT Newswires Live
·
Jun 24

Merck initiated with an Outperform at CICC

TIPRANKS
·
Jun 24

Movement Alert|Merck Rises 3.03% in Regular Trading, Multiple Catalysts Including Phase 3 Trial Success and Potential Major Acquisition

Market Focus
·
Jun 24

Scotiabank Reaffirms Their Buy Rating on Merck & Company (MRK)

TIPRANKS
·
Jun 23

Citi Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Jun 23

Merck (MRK) Stock Could Be 11% Undervalued After June Pipeline Wins

Simply Wall St.
·
Jun 23

Spanish stocks - Factors to watch on June 23

Reuters
·
Jun 23

Berenberg Bank Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Jun 23